In vitro and in vivo effects of fulvestrant combined with trastuzumab in breast cancer with estrogen receptor-positive and HER-2/neu-overexpressing

被引：0
|
作者：
Chen, Q. [1 ]
Wu, K. [1 ]
Lu, Y. [1 ]
Ding, L. [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Sch Med, Xin Hua Hosp, Gen Surg, Shanghai 200030, Peoples R China
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
421
引用
收藏
页码：S121 / S122
页数：2
相关论文
共 50 条
  • [1] Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer
    Massarweh, Suleiman
    Osborne, C. Kent
    Jiang, Shou
    Wakeling, Alan E.
    Rimawi, Mothaffar
    Mohsin, Syed K.
    Hilsenbeck, Susan
    Schiff, Rachel
    CANCER RESEARCH, 2006, 66 (16) : 8266 - 8273
  • [2] Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: A systematic review
    Madarnas, Yolanda
    Trudeau, Maureen
    Franek, Jacob A.
    McCready, David
    Pritchard, Kathleen I.
    Messersmith, Hans
    CANCER TREATMENT REVIEWS, 2008, 34 (06) : 539 - 557
  • [3] The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status
    Köstler, WJ
    Brodowicz, T
    Hudelist, G
    Rudas, M
    Horvat, R
    Steger, GG
    Singer, CF
    Attems, J
    Rabitsch, W
    Fakhrai, N
    Elandt, K
    Wiltschke, C
    Hejna, M
    Zielinski, CC
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2005, 131 (07) : 420 - 428
  • [4] The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status
    Wolfgang J. Köstler
    Thomas Brodowicz
    Gernot Hudelist
    Margaretha Rudas
    Reinhard Horvat
    Günther G. Steger
    Christian F. Singer
    Johannes Attems
    Werner Rabitsch
    Negar Fakhrai
    Katarzyna Elandt
    Christoph Wiltschke
    Michael Hejna
    Christoph C. Zielinski
    Journal of Cancer Research and Clinical Oncology, 2005, 131 : 420 - 428
  • [5] The effect of HER-2/neu inhibition on prolonging clinical benefit with fulvestrant treatment for metastatic estrogen receptor positive breast cancer patients treated with trastuzumab
    Charif, Mahmoud
    Lower, Elyse E.
    Kennedy, Diane
    Kumar, Harriet
    Khan, Shugufta
    Radhakrishnan, Neetu
    Zhang, Xiaoting
    CANCER RESEARCH, 2015, 75
  • [6] Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/NEU-overexpressing metastatic breast cancer
    Sawaki, M
    Ito, Y
    Tada, K
    Mizunuma, N
    Takahashi, S
    Horikoshi, N
    Kasumi, F
    Akiyama, F
    Sakamoto, G
    Imai, T
    Nakao, A
    Hatake, K
    TUMORI JOURNAL, 2004, 90 (01): : 40 - 43
  • [7] The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer
    Joe Yujiao Chang
    Weiya Xia
    Ruping Shao
    Frank Sorgi
    Gabriel N Hortobagyi
    Leaf Huang
    Mien-Chie Hung
    Oncogene, 1997, 14 : 561 - 568
  • [8] Amplification of Her-2/neu in Her-2/neu-overexpressing breast cancers and in associated synchronous benign and malignant lesions.
    Xu, R
    Feiner, H
    Inghirami, G
    Chan, W
    Delgado, Y
    Perle, MA
    LABORATORY INVESTIGATION, 2001, 81 (01) : 42A - 42A
  • [9] The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer
    Chang, JY
    Xia, WY
    Shao, RP
    Sorgi, F
    Hortobagyi, GN
    Huang, L
    Hung, MC
    ONCOGENE, 1997, 14 (05) : 561 - 568
  • [10] Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer
    Zhao, Shen
    Liu, Xi-Yu
    Jin, Xi
    Ma, Ding
    Xiao, Yi
    Shao, Zhi-Ming
    Jiang, Yi-Zhou
    THERANOSTICS, 2019, 9 (17): : 4935 - 4945
12345